BioDuro-Sundia Appoints Dr. Armin Spura as New Chief Executive Officer
BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the appointment of Dr. Armin Spura as its new Chief Executive Officer. Dr. Spura brings over two decades of experience in the life sciences and biotechnology sectors, with a proven track record of driving growth and innovation across global markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916598040/en/
Armin Spura, PhD, CEO, BioDuro-Sundia (Photo: Business Wire)
Dr. Spura joins BioDuro-Sundia from Crown Bioscience, where he served as the CEO for nearly five years, guiding the company through significant growth and strategic development. Throughout his career, Dr. Spura has held senior leadership positions at several well-known organizations such as Thermo Fisher Scientific, WuXi NEXTCODE, CareDx and Ion Torrent. He also holds various advisory roles, serving as the chair of the board of directors for SeromYx Systems and as a life science investment advisor at K2X Technology and Life Science.
Early in his career, Dr. Spura helped to grow two start-up companies: Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Dr. Spura studied biochemistry in Germany and received his Ph.D. in molecular biology from Brown University in the US.
“I am honored to join BioDuro-Sundia and lead this talented team as we embark on the next phase of growth,” said Dr. Spura. “With our unique, fully integrated CRDMO platform — encompassing chemistry, biology, DMPK, drug substance, and drug product from discovery through to commercial manufacturing — I am confident we will empower more partners to bring better treatments to patients around the world faster.”
Gary Chu, Chairman of the Executive Operation Committee of the company, added, “Dr. Spura’s extensive global experience and visionary leadership is instrumental in driving BioDuro-Sundia's accelerated growth. We are excited and confident that under his leadership, we will continue to innovate and deliver integrated solutions that meet growing needs from our clients worldwide and the broader healthcare community.”
About BioDuro-Sundia
BioDuro-Sundia, an Advent International portfolio company, is a CRDMO with a 28-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, with over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, DMPK, drug substance, and drug product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916598040/en/
Contacts
Christina Coby
Christina Coby
Marketing Manager
christina.coby@bioduro-sundia.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom